Abstract: A crystalline form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)-phenyl]-(6-methoxy-pyridazin-3-yl)-methanol can be prepared as a pharmaceutical composition.
Type:
Grant
Filed:
March 28, 2018
Date of Patent:
July 20, 2021
Assignee:
Merck Patent GmbH
Inventors:
Michael Lange, Clemens Kuehn, Thomas Fuchss, David Maillard, Marcel Breuning, Marco Poma, Edoardo Burini
Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.
Type:
Grant
Filed:
June 26, 2019
Date of Patent:
July 20, 2021
Assignee:
MERCK PATENT GMBH
Inventors:
Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
Abstract: The invention relates to a liquid-crystalline medium having a nematic phase comprising one or more compounds of formula B wherein the parameters have the meaning given in the text, to the use thereof in an electro-optical display, particularly in an active-matrix display based on the IPS or FFS effect, to displays of this type which contain a liquid-crystalline medium of this type and to the use of the compounds of formula B for improvement of the transmission and/or response times of a liquid-crystalline medium which comprises one or more additional mesogenic compounds.
Abstract: A fluid distributor valve (1) for repartitioning an inlet fluid stream (Z) into two outlet fluid streams (X, Y), comprising an inlet port (10), two outlet ports (11, 12), a first and a second valve mechanism (13, 14), one arranged upstream each outlet port (11, 12), wherein each valve mechanism (13, 14) comprises a valve body (15, 16) slidable in a cylindrical valve bore (17) in reciprocating strokes through a valve shaft (18), wherein the valve body (15, 16) includes a first portion (15a, 16a) that is formed with a progressively changing diameter so as to reduce a valve gap between the valve bore inner peripheral wall and the valve body outer peripheral wall at a plane (A, B) perpendicular to the stroke direction, in a regular operating range of the valve mechanism (13, 14), from a maximum valve gap to a minimum valve gap, to reduce or increase the flow rate through the gap towards the associated outlet port (11, 12) upon the relative movement, and wherein at least one of the valve bodies (15, 16) of the val
Abstract: The present invention relates to a novel anti-PD-L1 antibody formulation. In particular, the invention relates to an aqueous pharmaceutical formulation of the anti-PD-L1 antibody Avelumab.
Type:
Grant
Filed:
December 5, 2016
Date of Patent:
July 13, 2021
Assignees:
MERCK PATENT GMBH, PFIZER INC.
Inventors:
Gianluca Rinaldi, Alessandra Del Rio, Silvia Fratar-Cangeli, Senta Voss, Markus Weigandt
Abstract: [Problem] To provide a film forming composition curable at low temperature and a film forming method using the same. [Means for Solution] A film forming composition comprising a polysilazane, an organic solvent and aspecific additive, and a film forming method comprising applying it on a substrate and curing. The specific additive is selected from the group consisting of (A) guanidines substituted by a hydrocarbylgroup, (B) crown ether amines containing oxygen and nitrogen as a member thereof, (C) cycloalkanes having an amino-substituted polycyclic structure, (D) oximes substituted by a hydrocarbyl group, and (E) imidazolines.
Abstract: The present application relates to a substituted benzanthracene compound of a formula (I) or (II). The application furthermore relates to an electronic device which comprises the said benzanthracene compound.
Type:
Grant
Filed:
March 17, 2015
Date of Patent:
July 13, 2021
Assignee:
Merck Patent GmbH
Inventors:
Holger Heil, Lara-Isabel Rodriguez, Beate Burkhart, Sebastian Meyer
Abstract: An electronic switching element is described having, in sequence, a first electrode, a molecular layer bonded to a substrate, and a second electrode. The molecular layer contains compounds of formula I, R1-(A1-Z1)r—B1—(Z2-A2)s-Sp-G, wherein A1, A2, B1, Z1, Z2, Sp, G, r, and s are as defined herein, in which a mesogenic radical is bonded to the substrate via a spacer group, Sp, by means of an anchor group, G. The switching element is suitable for production of components that can operate as a memristive device for digital information storage.
Type:
Grant
Filed:
July 4, 2017
Date of Patent:
July 13, 2021
Assignee:
MERCK PATENT GMBH
Inventors:
Peer Kirsch, Andreas Ruhl, Marc Tornow, Achyut Bora
Abstract: [Problem] To provide a composition comprising polycarbosilane, which has excellent filling property, can form a film at a lower temperature, and makes electrical property of the produced film excellent. [Means for Solution] A silicon carbonaceous film forming composition comprising polycarbosilane and a solvent, wherein the ratio of the integrated intensity at 3.92 to 4.20 ppm to the integrated intensity at 3.60 to 5.50 ppm in the H-NMR spectrum of said polycarbosilane is 27 to 50%.
Abstract: The present invention relates to a composition comprising a nanosized light emitting material, and method for preparing of said composition. The present invention further relates to a light luminescent medium, a light emitting device, the present invention further more relates to method for preparing of a composition and to method for preparing of a light emitting medium.
Abstract: A liquid-crystalline medium having a nematic phase containing one or more compounds of formula D the use thereof in an electro-optical display, particularly in an active-matrix display based on the IPS or FFS effect, displays of this type which contain a liquid-crystalline medium of this type and the use of the compounds of formula D for improvement of the contrast and/or response times of a liquid-crystalline medium which contain one or more additional mesogenic compounds, as well as certain compounds of formula D.
Type:
Application
Filed:
December 18, 2020
Publication date:
July 8, 2021
Applicant:
Merck Patent GmbH
Inventors:
Sven Christian LAUT, Martina WINDHORST, Constanze BROCKE
Abstract: The invention relates to injectable pharmaceutical compositions comprising epinephrine, an antioxidant selected from the group consisting of sodium metabisulfite, sodium sulfite and sodium bisulfite, tartrate, a tonicity regulating agent, EDTA or Na2EDTA*2H2O and pH 3.0-4.5.
Type:
Application
Filed:
October 8, 2018
Publication date:
July 8, 2021
Applicant:
MERCK PATENT GMBH
Inventors:
Steffen AUGUSTIN, Thomas Artur Hendrik HERBST, Ulrich EMDE
Abstract: The present invention relates to a process for manufacturing dry powder cell culture media. The preparation and usage of mixed particles generated by co-lyophilisation leads to cell culture media with improved solubility without changing the chemical composition.
Type:
Application
Filed:
March 19, 2021
Publication date:
July 8, 2021
Applicant:
Merck Patent GmbH
Inventors:
Joerg VON HAGEN, Nikolai STANKIEWICZ, Anke SIMON
Abstract: The present invention relates to certain fluorenes, to the use of the compounds in an electronic device, and to an electronic device comprising at least one of these compounds. Furthermore, the present invention relates to a process for the preparation of the compounds and to a formulation and composition comprising one or more of the compounds.
Type:
Grant
Filed:
May 30, 2019
Date of Patent:
July 6, 2021
Assignee:
Merck Patent GmbH
Inventors:
Jochen Pfister, Frank Stieber, Elvira Montenegro, Teresa Mujica-Fernaud, Frank Voges
Abstract: An anhydrous disordered crystalline (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)-phenyl]-(6-methoxy-pyridazin-3-yl)-methanol can be used in pharmaceutical compositions.
Type:
Grant
Filed:
March 28, 2018
Date of Patent:
July 6, 2021
Assignee:
Merck Patent GmbH
Inventors:
Michael Lange, Clemens Kuehn, Thomas Fuchss, David Maillard, Marcel Breuníng, Marco Poma, Edoardo Burini
Abstract: The invention relates to a liquid crystal mixture characterised in that it comprises one or more photoreactive mesogens of formula I wherein the parameters and groups occurring are defined as indicated in claim 1, to a process for the fabrication of liquid crystal displays using these liquid crystal mixtures and to a liquid crystal display obtainable by this process. The invention further relates to new compounds of formula I.
Type:
Grant
Filed:
December 2, 2016
Date of Patent:
July 6, 2021
Assignee:
MERCK PATENT GMBH
Inventors:
Kevin Adlem, Alex Davis, Joseph Sargent, Ian Charles Sage, Edward Plummer, Izumi Saito, Rocco Fortte, Helga Haas, Lars Lietzau
Abstract: The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
Type:
Grant
Filed:
May 8, 2018
Date of Patent:
July 6, 2021
Assignee:
Merck Patent GmbH
Inventors:
Amir Parham, Jonas Kroeber, Dominik Joosten, Aurélie Ludemann, Tobias Grossmann
Abstract: Compounds of the formula (I), in which R1, R3, Het1 and HET have the meanings given in claim 1, are ATM kinase inhibitors and can be employed, inter alia, for the treatment of cancer.